巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    MediWound Ltd

    MDWD
    1.800
    0.050
    2.70%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・MediWound Ltd - 延遲價格・最後更新於 01/07 12:14
    最高位
    1.810
    最低位
    1.800
    開市價
    --
    前收市價
    1.850
    成交量(千)
    0.03
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    59.65
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.950 - 1.210
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    MediWound Ltd
    證券代碼
    MDWD.US
    所屬板塊
    Biotechnology
    公司業務
    MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States.
    發行量
    33140633
    公司總部
    42 Hayarkon Street
    公司網址
    https://www.mediwound.com
    公司電郵
    info@mediwound.com
    公司電話
    +972 779714100
    暫無內容

    關於

    MediWound Ltd(MDWD.US)所屬的行業板塊為Biotechnology。
    MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. Its first biopharmaceutical product, NexoBrid removes dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns also referred to as severe burns. NexoBrid is currently in clinical development in North America and is in the process of preparing its Biologics License Application. The company derives its revenue from the United States.
    詳細公司背景可參考: https://www.mediwound.com